This article is more than 5 years old. Information may no longer be current.

Patient enrollment begins in trial of fluid-controlled accommodating IOL

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first 10 patients in a multicenter clinical study have received the FluidVision IOL, according to a press release from PowerVision.

The study will assess the performance of the accommodating lens in cataract patients. Fluid inside the IOL moves in response to the natural muscle forces in the eye, becoming thicker when the patient needs to see up close or thinner when the patient needs to see distance, the release said.

This study is expected to include 115 participants undergoing cataract surgery at sites in South Africa and Germany. The study will form the basis for PowerVision’s CE mark of the FluidVision lens in the European Union, which is expected to occur next year, according to the release.